In Silico Classification of hERG Channel Blockers: a Knowledge‐Based Strategy
暂无分享,去创建一个
François Petitet | F. Petitet | E. Dubus | I. Ijjaali | Elodie Dubus | Ismaïl Ijjaali | André Michel | A. Michel
[1] Steven L. Dixon,et al. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..
[2] Luc Morin-Allory,et al. 2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database , 2004, J. Chem. Inf. Model..
[3] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[4] Roy J. Vaz,et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.
[5] Brian B. Goldman,et al. A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.
[6] A. Camm,et al. Drug induced QT prolongation and torsades de pointes , 2003, Heart.
[7] T. Nishikawa,et al. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[8] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[9] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[10] Christophe G. Lambert,et al. Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning , 1999, J. Chem. Inf. Comput. Sci..
[11] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[12] J. Tamargo. Drug-induced torsade de pointes: from molecular biology to bedside. , 2000, Japanese journal of pharmacology.
[13] M. Fligner,et al. Systematic analysis of large screening sets in drug discovery. , 2004, Current drug discovery technologies.
[14] J. Li,et al. A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.
[15] Alex M Aronov,et al. Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.
[16] G. Keserü. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.
[17] R. Lathe. Phd by thesis , 1988, Nature.
[18] P. Labute. A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.
[19] Gisbert Schneider,et al. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.
[20] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[21] A. Cavalli,et al. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development , 2005, Medicinal research reviews.
[22] John Sharkey,et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.
[23] Gabriele Cruciani,et al. Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.
[24] W. Crumb,et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.
[25] Gregory W. Kauffman,et al. Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.